Portal de Periódicos da CAPES

Differential miRNA plasma profiles associated with the spontaneous loss of HIV‐1 control: miR‐199a‐3p and its potential role as a biomarker for quick screening of elite controllers

2021; Springer Science+Business Media; Volume: 11; Issue: 7 Linguagem: Inglês

10.1002/ctm2.474

2001-1326

Jenifer Masip, Carmen Gasca‐Capote, María Reyes Jiménez‐León, Joaquim Peraire, Alberto Pérez‐Gómez, Verónica Alba, Ana Irene Malo, Lorna Leal, Carmen Rodríguez Martín, Norma Rallón, Consuelo Viladés, Montserrat Olona, Francesc Vidal, Ezequiel Ruiz‐Mateos, Anna Rull,

Advanced biosensing and bioanalysis techniques

People living with HIV (PLWH) who are able to maintain suppressed viral load (VL) for years in the absence of antiretroviral therapy (ART) are known as elite controllers (ECs). ECs represent a heterogeneous population in terms of virological, immunological, and clinical outcomes, and approximately 25% of ECs lose viral control overtime. The study of the mechanisms leading to the loss of viral control in ECs is crucial for the identification of differential markers for the design of novel eradication and immunotherapeutic strategies. Previously, we identified virological and immunological factors involved in the spontaneous loss of viral control,1 and we also demonstrated that proteomics and metabolomics are powerful tools to identify potential biomarkers and therapeutic targets in ECs.2, 3 Additionally, genome-wide associations and transcriptome analyses have also been described for ECs and compared to other phenotypes of PLWH,4, 5 in particular the study of specific microRNA (miRNA) expression profiles.5 miRNAs play vital roles in development, apoptosis, and oncogenesis by interfering with gene expression at the post-transcriptional level.6 In HIV/AIDS scenario, the most relevant feature is that some miRNAs can modulate HIV replication by directly targeting HIV RNA or targeting messenger RNA (mRNA) of cell factors necessary for HIV replication.7 Our study conducted in 18 ECs (Figure S1, Table S1), 12 individuals who experienced a loss of spontaneous viral HIV-1 control (transient controllers, TCs) and six ECs who persistently maintained viral control during the same follow-up period (persistent controllers, PCs), showed an upregulated plasma miRNA profile in TCs before and after the loss of viral control. First, 23 miRNAs were found differentially expressed in TCs compared to PCs at the preloss time point (Figure 1A, Table S2). From the 23 miRNAs, 22 miRNAs were positively correlated with viral load (VL), seven miRNAs were positively correlated with CD4+ T-cell counts, and 11 miRNAs were positively correlated with CD8+ T-cell counts (Table S3). Interestingly, the spontaneous loss of viral control in ECs can be defined by the expression of hsa-miR-27a-3p, hsa-miR-376a-3p, and hsa-miR-199a-3p (Figure 1B), as confirmed by the diagnostic accuracy determined by the ROC analysis (Figure 1C). Notably, hsa-miR-27a-3p, hsa-miR-376a-3p, and hsa-miR-199a are tightly connected and related to lipid metabolism (Figure 1D). Then, we also evaluated the plasma miRNA profile in TCs under the postloss condition and we found 38 miRNAs differentially expressed among groups, suggesting that viremia strongly influences the plasma miRNA profile of ECs (Figure 2A, Table S4). And again, these significantly expressed miRNAs among groups were also related to relevant genes linked to lipid pathways (Figure 2B), and some of them positively correlated with VL, CD4+ T-cell counts and CD8+ T-cell counts (Table S5). Moreover, of the 23 miRNAs significantly differentially expressed under the preloss condition and the 38 miRNAs significantly differentially expressed under the postloss condition, only the upregulation of 19 miRNAs overlapped (Figure 3A). Noteworthy, the expression of hsa-miR-199a-3p showed an optimal percentage of separation and an ability to differentiate between both groups of ECs before and after the loss of viral control (Figure 3B). Accordingly, the upregulation of hsa-miR-199a-3p could be related to lipid dysregulation in TCs, which in turn may potentiate the activation of a cytokine deregulation1 and in last term bias the virological control in TCs. Thus, our results confirmed differences in the expression of some miRNAs with target sites located in viral RNA regions encoding viral accessory proteins, suggesting the emerging concept that upregulated host-derived miRNAs in TCs might act as antiviral defence mechanism directly affecting important steps during HIV infection and also playing a key role in HIV immune pathogenesis. Notably, hsa-miR-423-3p targets the gag gene, hsa-miR-29a/29b and hsa-miR-326 target the nef gene, and hsa-miR-324-5p targets the vif gene6, 8 (Figure 4). One mechanism associated to the inhibitory effect of HIV replication could be the interaction of nef with the RISC complex, which leads to the inhibition of the translation of viral proteins and viral replication. On the other hand, Nef-containing exosomes, taken up by macrophages, have been suggested to impair lipid cholesterol efflux, causing intracellular cholesterol accumulation, which consequently affects the risk of cardiovascular diseases in PLWH.9, 10 Several miRNAs can regulate different steps of HDL-C metabolism, and recent studies have promoted the importance of miRNAs in controlling LDL metabolism and in the regulation of genes involved in very low-density lipoprotein (VLDL) secretion. Our results are in accord with these data since the LDL metabolism resulted to be increased in TCs under the postloss condition (Figure S2 and Figure S3).2 Additionally, some of the most representative host-derived miRNAs associated with the spontaneous loss of viral control overtime are liver-specific miRNAs, being implicated in fatty acid and cholesterol biosynthesis. Thus, our results suggest that disturbance in lipoprotein levels, mostly induced by upregulation of some liver-specific miRNAs, may be highly associated with the immunological factors behind the loss of viral control in TCs. It is known that HIV infection is characterized by a high energy demand to reprogram the cells to aerobic glycolytic pathways that consequently may increase anabolic metabolism.2 So, the increased lipid profile in TCs before the loss of viral control could be a consequence of the antiviral defence mechanism of the host against viral replication. The main limitation of this work is the small sample size. However, it must be highlighted that these patients are rare, and it is difficult to have a follow-up with sequentially stored samples. Despite the relatively low number of patients, we were able to have a tight follow-up of TCs with samples before and after the loss of virological control. Validation studies are needed to establish the proposed miRNAs as biomarkers for the loss of viral control in ECs. In conclusion, our study reveals a specific host-derived miRNA pattern in ECs that may be used as a biomarker for quick screening of the virological and immunological progression in ECs, and we confirmed that viremia induces increased LDL metabolism in TCs. Notably, the expression of liver-specific hsa-miR-199a-3p showed an optimal percentage of separation and an ability to differentiate between both groups of ECs before and after the loss of viral control. This study would not have been possible without the collaboration of all the patients and medical and nursing staff who took part in the project. These results were partially presented during the Virtual Conference on Retroviruses and Opportunistic Infections (CROI, 2021, Abstract number 2037). We also acknowledge the Biobanc IISPV (B.0000853 + B.0000854) integrated into the Biobanks and Biomodels Platform (PT20/00197) for its collaboration and CERCA Programme (Generalitat de Catalunya), ECRIS integrated in the Spanish AIDS Research Network (Annex S1), and BiosferTeslab, a spin-off company of the Rovira i Virgili University (URV) and the Pere Virgili Health Research Institute (IISPV). We also thank the comments and criticisms of the anonymous reviewers that greatly helped to improve the manuscript. Francesc Vidal is supported by grants from the Programa de Intensificación de Investigadores (INT20/00031)-ISCIII. Ezequiel Ruiz-Mateos was supported by Consejo Superior de Investigaciones Cientificas (CSIC). María del Carmen Gasca-Capote and María Reyes Jimenez-Leon were supported by ISCIII-FEDER, PFIS programme, FI19/00083 and FI17/00186, respectively. Anna Rull is supported by IISPV through the project "2019/IISPV/05″ (Boosting Young Talent), by GeSIDA through the "III Premio para Jóvenes Investigadores 2019," and by the Instituto de Salud Carlos III (ISCIII) under grant agreement "CP19/00146″ through the Miguel Servet Program. Jenifer Masip is supported by the Universitat Rovira i Virgili under grant agreement "2019PMF-PIPF-18" through the call "Martí Franquès Research Fellowship Programme." Norma Rallón is a Miguel Servet II investigator supported by a grant from the Instituto de Salud Carlos III (ISCIII) "CPII19/00025." All research protocols were approved and carried out according to the recommendations of the Ethical Committee for Clinical Research following the rules of Good Clinical Practice from the Institut d'Investigació Sanitària Pere Virgili (CEIm IISPV). The CEIM IISPV is an independent committee, made up of health and non-health professionals, which supervises the correct compliance of the ethical principles governing clinical trials and research projects that are carried out in our region, specifically in terms of methodology, ethics, and laws. All participants gave written informed consent in agreement with the Declaration of Helsinki. Fondo de Investigación Sanitaria-ISCIII-FEDER: PI13/0796, PI16/00503, PI16/0684, PI18/1532, PI19/01127, PI19/01337, PI20/00326, RD16/0025/0006, RD16/0025/0020, INT20/00031, FI19/00083, FI17/00186, CP19/00146, CPII19/00025. European Regional Development Fund/European Social Fund; Programa de Suport als Grups de Recerca AGAUR, Grant Number: 2017SGR948; Gilead Fellowship Program, Grant Number: GLD14/293; SPANISH AIDS Research Network, Grant Numbers: RD16/0025/0006, RD16/0025/0020 (ISCIII-FEDER, Spain). Programa de Intensificación de Investigadores, Grant Number: INT20/00031; Consejo Superior de Investigaciones Cientificas (CSIC); ISCIII-FEDER, PFIS programme, Grant Numbers: FI19/00083, FI17/00186; IISPV: 2019/IISPV/05 (Boosting Young Talent); GeSIDA "III Premio para Jóvenes Investigadores 2019″; Instituto de Salud Carlos III (ISCIII), Grant Number: CP19/00146; Universitat Rovira i Virgili, Grant Number: 2019PMF-PIPF-18; Instituto de Salud Carlos III (ISCIII), Grant Number: CPII19/00025 All authors reviewed and approved the submitted version of the manuscript. Experimental design: Jenifer Masip, Carmen Gasca-Capote, Ezequiel Ruiz-Mateos, and Anna Rull. Intellectual guidance: Consuelo Viladés, Joaquim Peraire, Francesc Vidal, Anna Rull, and Ezequiel Ruiz-Mateos. Recruitment of participants: Jenifer Masip, Ana-Irene Malo, Lorna Leal, Carmen Rodríguez Martín, Norma Rallón, Consuelo Viladés, Joaquim Peraire, Montserrat Olona, and Francesc Vidal. Sample procurement: Jenifer Masip and Verónica Alba. Data collection: Ezequiel Ruiz-Mateos, Ana-Irene Malo, Lorna Leal, Carmen Rodríguez Martín, Norma Rallón, Consuelo Viladés, Joaquim Peraire, and Montserrat Olona. Data analysis and interpretation: Jenifer Masip, María del Carmen Gasca-Capote, María Reyes Jimenez-Leon, Alberto Perez-Gomez, Ezequiel Ruiz-Mateos, and Anna Rull. Manuscript preparation: Jenifer Masip, María del Carmen Gasca-Capote, Ezequiel Ruiz-Mateos, and Anna Rull. Study design, data analysis, and article development: Jenifer Masip, Anna Rull, Ezequiel Ruiz-Mateos, and Francesc Vidal. Reviewed and edited the manuscript: Francesc Vidal, Anna Rull, and Ezequiel Ruiz-Mateos. The data that support the findings of this study are available from the corresponding author upon reasonable request. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.